摘要
肝肾综合征(HRS)是发生在肝硬化失代偿或急慢性肝衰竭患者中的一种严重并发症。HRS以外周血管显著扩张和肾动脉强烈收缩为主要病理特征,临床进展快,治疗效果欠佳,预后差。药物治疗中以血管收缩性药物为主,特利加压素联合白蛋白是目前HRS的一线治疗方法,一些具有扩张肾脏血管作用的药物具有潜在的治疗作用。阐述了HRS治疗中血管活性药物的作用和临床应用的研究进展。
Hepatorenal syndrome(HRS)is a serious complication that occurs in patients with decompensated cirrhosis or acute/chronic liver failure.The main pathological features of HRS include marked peripheral vasodilation and strong renal vasoconstriction,with rapid progression,unsatisfactory treatment response,and poor prognosis.Vasoconstrictors are mainly used in the pharmacotherapy for HRS,and at present,terlipressin combined with albumin is the first-line treatment method for HRS.Some drugs with a renal vasodilatory effect also show a potential therapeutic effect.This article reviews the latest research advances in the role and clinical application of vasoactive drugs in the treatment of HRS.
作者
李晓芸
华静
LI Xiaoyun;HUA Jing(Department of Gastroenterology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai Institute of Digestive Disease,Shanghai 200001,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2020年第11期2419-2422,共4页
Journal of Clinical Hepatology
基金
国家自然科学基金(81470842,81770572)。
关键词
肝肾综合征
血管收缩药
治疗学
hepatorenal syndrome
vasoconstrictor agents
therapeutics
